CVS Health Corporation (CVS) 2026 Q3 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Hello, and welcome to CVS Health’s third-quarter 2026 earnings call. (Operator Instructions)

    大家好,歡迎參加 CVS Health 2026 年第三季財報電話會議。(接線員指示)

  • As a reminder, this conference is being recorded today. If you have any objections, please disconnect at this time. I would now like to pass the call to Larry McGrath. Larry, please proceed.

    提醒各位,本次會議今日將進行錄音。如有任何異議,請此刻中斷連線。現在我想把電話交給 Larry McGrath。Larry,請開始。

  • Larry Mcgrath - Executive Vice President, Capital Markets

    Larry Mcgrath - Executive Vice President, Capital Markets

  • Good morning, and welcome to the CVS Health third-quarter 2026 earnings and business update call and webcast. I’m Larry McGrath, Executive Vice President of Capital Markets at CVS Health. I’m joined this morning by David Joyner, Chairman and Chief Executive Officer; and Brian Newman, Chief Financial Officer. Following our prepared remarks, we’ll host a question-and-answer session that will include additional members of the leadership team.

    各位早安,歡迎參加 CVS Health 2026 年第三季財報與業務更新電話會議及網路直播。我是 CVS Health 資本市場執行副總裁 Larry McGrath。今天早上與我一同出席的有董事長兼執行長 David Joyner,以及財務長 Brian Newman。在我們的事先準備發言之後,我們將進行問答環節,屆時也會有領導團隊的其他成員加入。

  • Our press releases and slide presentations have been posted to our website, along with our Form 10-Q filed this morning with the SEC. Today’s call is also being broadcast on our website.

    我們的新聞稿與簡報已發布於公司網站,並包含我們今早向美國證券交易委員會(SEC)提交的 Form 10-Q。今天的電話會議也會在我們的網站上同步播出。

  • During this call, we’ll make certain forward-looking statements. Our forward-looking statements are subject to significant risks and uncertainties that could cause actual results to differ materially from currently projected results.

    在本次電話會議中,我們將作出若干前瞻性陳述。我們的前瞻性陳述受到重大風險與不確定性的影響,可能導致實際結果與目前預測結果出現重大差異。

  • We strongly encourage you to review the reports we file with the SEC regarding these risks and uncertainties, in particular those that are described in the cautionary statement concerning forward-looking statements and risk factors in our most recent annual report on Form 10-K, our quarterly report on Form 10-Q filed this morning, and our recent filings on Form 8-K, including this morning’s earnings press release.

    我們強烈建議各位查閱我們向 SEC 提交的報告,以了解這些風險與不確定性,特別是我們最新的 Form 10-K 年度報告、今早提交的 Form 10-Q 季度報告,以及近期提交的 Form 8-K 文件中所載的「前瞻性陳述注意事項」與風險因素,包括今早的財報新聞稿。

  • During this call, we’ll use certain non-GAAP measures when talking about the company’s financial performance and financial condition, and you can find a reconciliation of these non-GAAP measures in this morning’s press release and in the reconciliation document posted to the investor relations portion of our website.

    在本次電話會議中,當我們談及公司財務表現與財務狀況時,將使用若干非 GAAP 指標;您可在今早的新聞稿以及發布於我們網站投資人關係專區的調節文件中,找到這些非 GAAP 指標的調節表。

  • With that, I’d like to turn the call over to David. David?

    接下來,我想把電話交給 David。David?

  • David Joyner - Chairman and Chief Executive Officer

    David Joyner - Chairman and Chief Executive Officer

  • Thank you, Larry, and good morning, everyone. Our organization has a long and distinguished history, and in my 40 years at this company, there has been one constant: we act, we evolve, and we proactively shape the future of healthcare. Today, we announced our intention to separate into two independent publicly traded companies. This decision marks the next important chapter in the evolution of CVS Health.

    謝謝你,Larry,各位早安。我們的組織擁有悠久且卓越的歷史,而在我於本公司服務的 40 年中,有一件事始終不變:我們採取行動、持續演進,並主動塑造醫療照護的未來。今天,我們宣布有意分拆為兩家獨立的公開上市公司。這項決策標誌著 CVS Health 演進歷程中的下一個重要篇章。

  • We are creating two distinct leaders in healthcare. The first will be a healthcare solutions company that brings together medical, pharmacy, specialty, and care delivery capabilities integrated where it matters. In the interim period, we are referring to this business as CVS Health.

    我們正在打造兩個在醫療照護領域各自領先的企業。第一家將是醫療照護解決方案公司,整合醫療、藥局、專科與照護提供等能力,並在關鍵之處實現整合。在過渡期間,我們將此業務稱為 CVS Health。

  • The second company will be a leading national retail pharmacy and community healthcare company. This business will be named CVS Pharmacy. Both companies will be led by experienced leadership teams, have a clear right to win in their respective markets, and we expect will be supported by solid investment-grade balance sheets, enabling each company to pursue disciplined and tailored capital allocation.

    第二家公司將是全國領先的零售藥局與社區醫療照護公司。此業務將命名為 CVS Pharmacy。兩家公司都將由經驗豐富的領導團隊帶領,在各自市場具備明確的致勝優勢;我們預期兩家公司都將由穩健的投資等級資產負債表所支撐,使各公司得以推動審慎且量身打造的資本配置。

  • We take this action from a position of strength, which you can see in the consistent progress we’ve made since 2024, as well as in the third quarter results and the updated guidance we announced this morning. This quarter, we generated adjusted operating income of $4.2 billion and adjusted EPS of $2.09. Building on our continued strong performance so far this year, we are raising our full year 2026 adjusted EPS guidance to at least $8.20, an increase from our prior range of $7.90 to $8.10.

    我們是在實力堅實的基礎上採取此行動,這可從我們自 2024 年以來持續取得的進展,以及第三季業績與我們今早公布的最新財測指引中看出。本季,我們創造了 42 億美元的調整後營業利益與 2.09 美元的調整後每股盈餘(EPS)。在今年迄今持續強勁表現的基礎上,我們將 2026 全年調整後 EPS 指引上調至至少 8.20 美元,高於先前 7.90 至 8.10 美元的區間。

  • We are also updating our full year expectation for cash flow from operations to at least $15.5 billion. With this latest update, our 2026 adjusted EPS guidance is now more than $1 above our initial expectations for 2026, and our cash flow from operations outlook has increased by more than $5.5 billion for the year. This progress clearly reflects our growing momentum. I’ll now ask Brian to provide more details on the results this quarter, our updated full year 2026 guidance, and perspective on the factors shaping our 2027 expectations.

    我們也將 2026 全年營運活動現金流量的預期更新為至少 155 億美元。隨著這次最新更新,我們 2026 年調整後 EPS 指引現已較最初對 2026 年的預期高出超過 1 美元,而營運活動現金流量展望則較年初提高超過 55 億美元。這些進展清楚反映出我們動能正在增強。接下來我請 Brian 提供更多本季業績細節、更新後的 2026 全年指引,以及影響我們 2027 年預期的因素觀點。

  • I will then come back to provide more details on our announcement. Brian?

    之後我會再回來,進一步說明我們今天的公告。Brian?

  • Brian Newman - Chief Financial Officer, Executive Vice President

    Brian Newman - Chief Financial Officer, Executive Vice President

  • Thank you, David, and good morning. I will cover four key topics in my remarks this morning. First, an update on our third-quarter results. Second, I’ll discuss cash flow, the balance sheet, and capital deployment. After that, I will provide an updated financial outlook for 2026. Finally, I will share some headwinds and tailwinds as we look ahead to 2027.

    謝謝你,David,各位早安。我今天早上的發言將涵蓋四個重點主題。第一,第三季業績更新。第二,我將討論現金流、資產負債表與資本運用。接著,我會提供 2026 年更新後的財務展望。最後,展望 2027 年,我將分享一些逆風與順風因素。

  • Our third-quarter results demonstrate the discipline with which we continue to manage the enterprise. We once again delivered on our commitments and raised our full year outlook for revenue, adjusted EPS, and cash flow from operations. Our execution has significantly strengthened our balance sheet, allowing us to achieve target leverage ahead of schedule, and will enable us to resume our share repurchase program in the fourth quarter.

    我們第三季的結果展現了我們持續以紀律管理整體企業的作風。我們再次達成承諾,並上調全年營收、調整後 EPS 與營運活動現金流量的展望。我們的執行已顯著強化資產負債表,使我們得以提前達成目標槓桿水準,並將讓我們在第四季恢復股票回購計畫。

  • Let me start by highlighting some of our enterprise results in the quarter. We generated over $108 billion of revenue and delivered nearly $4.2 billion of adjusted operating income, once again reflecting earnings growth across all of our operating segments. We delivered adjusted EPS of $2.09, an increase of over 30% from the prior year quarter. Finally, in the quarter, we generated cash flow from operations of approximately $4.7 billion, bringing our year-to-date cash flow from operations to $15.3 billion.

    我先強調本季一些整體企業層面的成果。我們創造了超過 1,080 億美元的營收,並實現接近 42 億美元的調整後營業利益,再次反映我們所有營運部門的獲利成長。我們的調整後 EPS 為 2.09 美元,較去年同期成長超過 30%。最後,本季我們產生約 47 億美元的營運活動現金流量,使今年迄今的營運活動現金流量達到 153 億美元。

  • Turning now to each of our segments. In Health Care Benefits, we continue to make strong progress in our return to target margins. In the quarter, we delivered adjusted operating income of approximately $900 million, an increase of nearly $600 million from the prior year quarter. Our medical benefit ratio was 91.3%, an improvement of approximately 150 basis points from the prior year. These results were primarily driven by improved underlying performance in our Medicare business.

    接下來談各業務部門。在醫療保險福利(Health Care Benefits)方面,我們持續在回到目標利潤率的進程上取得強勁進展。本季我們實現約 9 億美元的調整後營業利益,較去年同期增加近 6 億美元。我們的醫療給付比率(medical benefit ratio)為 91.3%,較去年同期改善約 150 個基點。這些結果主要由我們 Medicare 業務的基礎表現改善所帶動。

  • Across our businesses, we continue to successfully navigate elevated trends that remain above historical levels throughout the industry but were broadly in line with our expectations. Performance in our Medicare book modestly exceeded our expectations, driven by pockets of favorability as a result of strong medical cost management and disciplined pricing.

    在各項業務中,我們持續成功因應仍高於歷史水準的上升趨勢;該趨勢在整個產業普遍存在,但整體上與我們的預期大致一致。我們的 Medicare 承保組合(book)表現略優於預期,主要受惠於部分有利因素,來自強勁的醫療成本管理與審慎的定價。

  • We remain confident in the adequacy of our reserves. In our Health Services segment, we continue to execute against our objectives. During the quarter, we delivered adjusted operating income of $2.1 billion, an increase of nearly 3% from the prior year quarter, primarily driven by improved purchasing economics and pharmacy drug mix, partially offset by continued pharmacy client price improvements. Results in our Pharmacy Services business were in line with our expectations during the quarter, including performance in both our 340B business and rebate guarantees.

    我們仍對準備金的充足性充滿信心。在健康服務(Health Services)部門,我們持續依照目標推進執行。本季我們實現 21 億美元的調整後營業利益,較去年同期增加近 3%,主要由採購經濟效益改善與藥局用藥組合帶動,但部分被藥局客戶價格持續改善所抵銷。本季我們藥局服務(Pharmacy Services)業務的結果符合預期,包括 340B 業務與回扣保證(rebate guarantees)的表現。

  • Health Care Delivery also performed as expected as we continue to drive improvement in the business. Our Pharmacy and Consumer Wellness segment delivered another strong quarter. We generated adjusted operating income of over $1.6 billion, an increase of over 10% from the prior year, primarily driven by core pharmacy strength, including a nearly 4% increase in same-store prescription volumes, partially offset by continued business investments and the impact of consumer dynamics.

    醫療照護提供(Health Care Delivery)的表現也符合預期,我們持續推動該業務改善。我們的藥局與消費者健康(Pharmacy and Consumer Wellness)部門再度交出強勁的一季。我們創造了超過 16 億美元的調整後營業利益,較去年同期成長超過 10%,主要由核心藥局業務的強勁表現所帶動,包括同店處方量成長近 4%;但部分被持續的業務投資與消費者動態的影響所抵銷。

  • Turning now to cash flow and the balance sheet. Year to date, we have generated cash flow from operations of $15.3 billion, reflecting strong earnings as well as the impact of improvements in working capital. So far in 2026, we have returned nearly $2.6 billion to our shareholders through our shareholder dividend. We ended the quarter with nearly $6 billion of cash at the parent and unrestricted subsidiaries.

    現在轉到現金流與資產負債表。年初至今,我們已產生153億美元的營運活動現金流,反映強勁獲利表現,以及營運資金改善所帶來的影響。截至2026年目前為止,我們已透過股東股利向股東返還近26億美元。本季末,母公司及不受限制之子公司合計持有近60億美元現金。

  • As I mentioned earlier, we have made significant progress strengthening our balance sheet and have achieved our leverage goal ahead of schedule. This improved position, combined with our strong cash flow, will enable us to resume our share repurchase program in the fourth quarter.

    如我先前提到的,我們在強化資產負債表方面已取得顯著進展,並提前達成我們的槓桿目標。這項改善的狀況,加上我們強勁的現金流,將使我們得以在第四季恢復股票回購計畫。

  • Shifting now to our guidance for 2026. We are increasing our full-year 2026 guidance for adjusted EPS to at least $8.20, an increase of $0.20 from the midpoint of our previous outlook. We now also expect our full-year total revenues to be at least $420 billion.

    接著談我們對2026年的財測指引。我們將2026年全年調整後每股盈餘(adjusted EPS)指引上調至至少8.20美元,較先前展望中點提高0.20美元。我們現在也預期全年總營收至少為4,200億美元。

  • In our Health Care Benefits segment, we now expect full-year adjusted operating income to be at least $5.4 billion, an increase of $200 million relative to the midpoint of our prior outlook. We now expect our full-year MBR to be in the lower half of our previously discussed range of 89.75%, plus or minus 25 basis points. This outlook continues to maintain a respectful and prudent view of medical cost trends.

    在健康照護福利(Health Care Benefits)部門,我們現在預期全年調整後營業利益至少為54億美元,較先前展望中點增加2億美元。我們現在預期全年醫療福利比率(MBR)將落在先前所討論89.75%區間的下半部,正負25個基點。此展望仍維持對醫療成本趨勢的尊重且審慎的看法。

  • In our Pharmacy and Consumer Wellness segment, we now expect full-year adjusted operating income of at least $6.5 billion, an increase of $100 million from our prior guidance and nearly 8% growth from the prior year. This reflects our strong performance in the quarter and our updated expectations for the remainder of the year. We are also reiterating our full-year adjusted operating income outlook for our Health Services segment. In aggregate, we now expect full-year enterprise adjusted operating income to be at least $17.05 billion.

    在藥局與消費者健康(Pharmacy and Consumer Wellness)部門,我們現在預期全年調整後營業利益至少為65億美元,較先前指引增加1億美元,並較去年成長近8%。這反映本季的強勁表現,以及我們對今年剩餘期間的最新預期。我們也重申健康服務(Health Services)部門的全年調整後營業利益展望。整體而言,我們現在預期全年企業層級調整後營業利益至少為170.5億美元。

  • We are also increasing our outlook for full-year cash flow from operations to at least $15.5 billion, reflecting our updated earnings outlook as well as the impact of working capital improvements and the timing of certain payments. Cash generation has long been a strength of this enterprise, and we continue to build on that strength as we deliver on our embedded earnings and unlock further working capital efficiencies. You can find additional details on the components of our updated 2026 guidance on our investor relations website.

    我們也將全年營運活動現金流展望上調至至少155億美元,反映我們更新後的獲利展望,以及營運資金改善與部分付款時點的影響。現金創造長期以來一直是本企業的強項;在我們兌現既有獲利動能並釋放更多營運資金效率之際,我們將持續強化這項優勢。您可在我們的投資人關係網站上找到更新後2026年指引各項組成的更多細節。

  • Turning now to 2027. Consistent with past practice, we expect to provide formal 2027 guidance on our fourth quarter earnings call early next year. Today, I will share an update on some of the key headwinds and tailwinds we are considering for 2027.

    接著談2027年。依循過往慣例,我們預期將於明年年初的第四季財報電話會議上提供正式的2027年指引。今天,我將分享我們在評估2027年時所考量的一些關鍵逆風與順風的最新情況。

  • Starting first with our healthcare benefits business, we expect another year of meaningful margin improvement as Aetna makes strong progress on its path back to target margins. Once again, this improvement will be largely driven by the deliberate actions we took in our Medicare Advantage business, along with continued disciplined underwriting and pricing across our businesses in response to the elevated trend environment we expect will persist in 2027.

    先從我們的健康照護福利業務談起,隨著Aetna在回到目標利潤率的路徑上取得強勁進展,我們預期利潤率將再迎來一年顯著改善。同樣地,這項改善將主要由我們在Medicare Advantage業務中所採取的審慎行動所驅動,並且在我們預期2027年仍將持續的高趨勢環境下,於各項業務中持續維持嚴謹的核保與定價紀律。

  • In our Health Services segment, we expect to generate adjusted operating income of at least $7 billion. This includes our previously discussed expectations for a year-on-year decline in our 340B business, as well as headwinds from the impact of a less robust selling season and health plan client membership attrition. We also expect tailwinds from continued strength in specialty and another year of improvement in our healthcare delivery business.

    在健康服務(Health Services)部門,我們預期可創造至少70億美元的調整後營業利益。其中包含我們先前所討論的340B業務年對年下滑的預期,以及因銷售季不如以往強勁與健康計畫客戶會員流失所帶來的逆風。我們也預期專科領域持續強勁將帶來順風,並且我們的醫療照護交付(healthcare delivery)業務將再迎來一年改善。

  • We continue to expect our 340B business to largely stabilize by the end of next year, and we have confidence as we enter the 2028 PBM selling season. We are confident 2027 will reflect trough earnings for the segment, and we expect to return to growth from there.

    我們仍預期340B業務將在明年年底前大致趨於穩定,並且在進入2028年PBM銷售季時具備信心。我們有信心2027年將反映該部門的獲利谷底,並預期之後將回到成長軌道。

  • In our Pharmacy and Consumer Wellness business, we expect adjusted operating income to grow low single digits off our current 2026 guidance of at least $6.5 billion, driven by continued pharmacy strength. This marks the third consecutive year of growth in earnings for this segment. Our updated outlook reflects the progress we’ve made differentiating our business and solidifying our position as the best-run national pharmacy, while maintaining a prudent view of consumer dynamics.

    在藥局與消費者健康(Pharmacy and Consumer Wellness)業務方面,我們預期調整後營業利益將在目前2026年指引(至少65億美元)的基礎上呈現低個位數成長,主要由藥局業務持續強勁所帶動。這將是該部門連續第三年獲利成長。我們更新後的展望反映我們在差異化業務、鞏固作為營運最佳的全國性藥局地位方面所取得的進展,同時對消費者動態維持審慎看法。

  • Pulling it all together and reflecting the strong performance we saw in the third quarter, we now expect to deliver at least $8.65 in adjusted EPS in 2027, reflecting approximately 13% growth off an adjusted 2026 baseline. Our strong results demonstrate the progress we’re making across the enterprise. We’ve strengthened our financial position, created greater capacity for capital deployment, and built increased confidence in the long-term expectations we outlined at Investor Day. We now believe we will be in the high end of our mid-teens adjusted EPS CAGR through 2028.

    綜合以上並反映我們在第三季看到的強勁表現,我們現在預期2027年可達成至少8.65美元的調整後每股盈餘(adjusted EPS),相較於調整後2026年基準約成長13%。我們的強勁成果展現我們在全企業範圍內所取得的進展。我們已強化財務狀況、提升資本配置能力,並對我們在投資人日所提出的長期預期建立更高信心。我們現在相信,至2028年為止,我們將落在調整後EPS年複合成長率(CAGR)中十位數(mid-teens)區間的高端。

  • Importantly, these expectations remain grounded in the same guidance philosophy of establishing credible targets, delivering with disciplined execution, and highlighting opportunities for outperformance. We will continue delivering on our say-do ratio, and that discipline will remain as we progress towards separation.

    重要的是,這些預期仍建立在相同的指引理念之上:設定可信的目標、以嚴謹的執行交付成果,並凸顯超越預期的機會。我們將持續兌現「說到做到」的比率(say-do ratio),且在我們朝分拆邁進的過程中,這份紀律將持續不變。

  • With that, I’ll now turn the call back over to David. David?

    接下來,我把電話交回給David。David?

  • David Joyner - Chairman and Chief Executive Officer

    David Joyner - Chairman and Chief Executive Officer

  • Thank you, Brian. As Brian highlighted, we are executing against our strategy, and our businesses continue to deliver durable results. Today, we announce that we are building on that momentum. CVS Health is taking an important step in its evolution to create two independent publicly traded companies. Each of the two companies will remain a leader in their respective markets, powered by the right assets, the right focus, and the ability to adapt and move faster. We can take this strategic action today because of our tremendous progress since 2024.

    謝謝你,Brian。如Brian所強調的,我們正依策略推進執行,而各項業務也持續交出具韌性的成果。今天,我們宣布將在這股動能之上再向前推進。CVS Health正採取其演進過程中的重要一步,打造兩家彼此獨立、公開上市的公司。兩家公司將各自在其市場中維持領導地位,並由合適的資產、合適的聚焦,以及更快適應與行動的能力所驅動。我們之所以能在今天採取這項策略行動,是因為自2024年以來我們取得了巨大的進展。

  • We rebuilt our leadership team and instilled a clear culture of accountability, excellence, and execution across the organization. We significantly improved our financial performance, strengthened our balance sheet, and reached our target leverage ratio ahead of schedule, creating capacity for disciplined capital deployment.

    我們重建了領導團隊,並在全組織灌輸清晰的問責、卓越與執行文化。我們大幅改善財務表現、強化資產負債表,並提前達成目標槓桿比率,從而建立起可進行有紀律資本配置的能力。

  • We expanded our technology capabilities across our enterprise, thoughtfully embedding AI throughout our businesses and creating a differentiated foundation to simplify and improve the healthcare experience. As we’ve consistently demonstrated, we are making great strides delivering against our goals while remaining focused on improving the health and care of the 185 million people we serve. As we have advanced our strategy, the environment around us is constantly changing. We will be better positioned to address this changing environment as two strong independent healthcare leaders.

    我們在全企業範圍內擴展科技能力,審慎地將AI嵌入各項業務之中,並打造差異化的基礎,以簡化並改善醫療照護體驗。如我們一貫所展現的,我們在達成目標方面取得長足進展,同時仍專注於改善我們所服務的1.85億人的健康與照護。隨著我們推進策略,周遭環境也在不斷變化。作為兩家強而獨立的醫療照護領導者,我們將更有利於因應這個變動的環境。

  • Following a thoughtful and deliberate strategic review by the board and senior management, we have a structure and plan that are built to win and represent the best path to create value over the long term. As we announced, CVS Health will retain Aetna, Caremark, and Pharmacy Services, Specialty Pharmacy, Oak Street, and Signify Health.

    在董事會與高階管理團隊進行周延且審慎的策略檢視後,我們制定了旨在致勝的架構與計畫,並代表創造長期價值的最佳路徑。如我們所宣布,CVS Health將保留Aetna、Caremark與藥局服務(Pharmacy Services)、專科藥局(Specialty Pharmacy)、Oak Street,以及Signify Health。

  • This enables us to maintain and expand integration where it matters, combining the tools necessary to improve affordability within medical and pharmacy benefits and deliver care to high-acuity populations, including in Medicare and Specialty Pharmacy. CVS Pharmacy will be the leading national retail pharmacy and community healthcare company. It will include our retail pharmacy stores, mail order, MinuteClinic, and Health100, our AI-native integrated healthcare engagement platform for consumers. The rationale for the separation is simple, with four clear benefits.

    這使我們能在關鍵之處維持並擴大整合,結合改善醫療與藥局福利可負擔性所需的工具,並為高病況嚴重度族群提供照護,包括在Medicare與專科藥局領域。CVS Pharmacy將成為領先的全國性零售藥局與社區醫療照護公司。其將包含我們的零售藥局門市、郵購服務、MinuteClinic,以及Health100——我們面向消費者、以AI為原生(AI-native)的整合式醫療互動平台。分拆的理由很簡單,並具有四項明確的效益。

  • First, focus. Each company will have an experienced, dedicated leadership team that can concentrate on the areas where it has the greatest opportunity to create value. The same mission, sharper focus. Second, capital allocation. Each company is expected to have a solid investment-grade capital structure and strong free cash flow. This will enable tailored capital allocation, more closely aligned with each company’s strategy and growth opportunities.

    首先,聚焦。每家公司都將擁有一支經驗豐富、專注投入的領導團隊,能夠把精力集中在其最有機會創造價值的領域。相同的使命,更銳利的聚焦。第二,資本配置。預期每家公司都將具備穩健的投資級資本結構與強勁的自由現金流。這將使資本配置得以量身打造,並與各公司的策略與成長機會更緊密對齊。

  • What will not change is the discipline that each company demonstrates in the deployment of capital. Third is agility. Each company will have greater flexibility to adopt the technologies that best fit its needs, improve efficiency, and more effectively adapt to the regulatory and other external dynamics. As independent companies, we will innovate and move faster as we work to improve how healthcare is experienced today.

    不會改變的是,各家公司在資本運用上所展現的紀律。第三是敏捷性。每家公司將擁有更大的彈性,採用最符合其需求的技術、提升效率,並更有效地因應監管及其他外部動態。作為獨立公司,我們在致力改善當今醫療照護體驗的同時,將更快創新與推進。

  • Finally, and importantly, simplicity. Greater independence will make it easier to serve consumers, members, patients, and communities, and will create opportunities for each company to pursue a broader range of partnerships. By taking this deliberate action, we are creating simpler, stronger, and more focused companies. CVS Health will be a scaled health solutions company with attractive growth and strong cash flow generation.

    最後且同樣重要的是,簡化。更高的獨立性將使我們更容易服務消費者、會員、病患與社區,並為各公司追求更廣泛的合作夥伴關係創造機會。透過這項審慎的行動,我們正在打造更簡單、更強大、也更聚焦的公司。CVS Health 將成為具規模的健康解決方案公司,擁有具吸引力的成長性與強勁的現金流創造能力。

  • This business will preserve a well-diversified mix of assets and capabilities to address a $2-plus trillion growing market across Medicare, commercial, and Medicaid. We will stay relentlessly focused on affordability, access, and health outcomes. I will serve as Chairman and CEO alongside the best-in-class leadership team in place today. CVS Pharmacy will be the national leader in pharmacy and community healthcare.

    此業務將保有高度多元化的資產與能力組合,以因應橫跨 Medicare、商業保險與 Medicaid、規模超過 2 兆美元且持續成長的市場。我們將持續堅定聚焦於可負擔性、可近性與健康結果。我將擔任董事長兼執行長,並與目前在位、同級最佳的領導團隊共同帶領。CVS Pharmacy 將成為藥局與社區醫療照護的全國領導者。

  • Our investments in technology and our colleagues continue to set us apart in this greater than a $500 billion market. This is an economically resilient sector where prescription growth will continue to be driven by medical innovation and demographics. CVS Pharmacy will build on its position as the most trusted and most frequent consumer touchpoint in healthcare.

    我們在科技與同仁上的投資,持續讓我們在這個超過 5,000 億美元的市場中脫穎而出。這是一個具經濟韌性的產業,處方量成長將持續由醫療創新與人口結構所驅動。CVS Pharmacy 將在其作為醫療照護中最受信賴、且最頻繁的消費者接觸點之地位上再接再厲。

  • Prem Shah, currently the Group President of CVS Health, will become CEO of CVS Pharmacy upon separation. He will be supported by the experienced leaders and colleagues who reset the trajectory and reinvigorated our retail pharmacy business. With attractive growth, enviable cash flow, and a strong balance sheet, CVS Pharmacy will be a unique asset across healthcare and retail.

    現任 CVS Health 集團總裁的 Prem Shah,將在分拆後出任 CVS Pharmacy 執行長。他將在資深領導團隊與同仁的支持下,延續他們扭轉趨勢並重振我們零售藥局業務的成果。憑藉具吸引力的成長、令人稱羨的現金流與強健的資產負債表,CVS Pharmacy 將成為橫跨醫療照護與零售領域的獨特資產。

  • Both companies remain committed to unlocking the tremendous potential of Health100, our AI-native consumer engagement platform. The mission of Health100 remains unchanged, to be the front door of health and care.

    兩家公司仍將致力於釋放 Health100(我們以 AI 為原生的消費者互動平台)的巨大潛力。Health100 的使命維持不變:成為健康與照護的前門入口。

  • By focusing on consumers, Health100 will truly change the way healthcare is experienced in this country. We will drive greater interoperability to remove friction from the system and engage with consumers in a way that no one else has ever done before. We believe this separation will accelerate the adoption and development of Health100 and allow us to drive innovation, improve connectivity, and unlock greater value across both companies.

    透過聚焦消費者,Health100 將真正改變本國的醫療照護體驗方式。我們將推動更高程度的互通性,以消除系統摩擦,並以過去從未有人做到的方式與消費者互動。我們相信,此次分拆將加速 Health100 的採用與發展,並使我們能推動創新、提升連結性,並在兩家公司之間釋放更大的價值。

  • We expect the separation transaction to be tax-free for US federal income tax purposes and to be completed in the first half of 2028, subject to customary conditions, including final board approval, Form 10 effectiveness, and receipt of customary tax confirmation.

    我們預期分拆交易就美國聯邦所得稅目的而言將為免稅,並預計在 2028 年上半年完成,但仍須符合慣常條件,包括董事會最終核准、Form 10 生效,以及取得慣常的稅務確認。

  • Following separation, CVS Health shareholders will own shares in both companies. We will be transparent about our progress, and we will provide additional details along the way. I want to emphasize that we will not lose sight of the need to execute with excellence every single day and consistently deliver on our commitments to all of our stakeholders.

    分拆完成後,CVS Health 股東將同時持有兩家公司的股份。我們將就進展保持透明,並在過程中提供更多細節。我想強調的是,我們不會忽視每天以卓越執行的必要性,並將持續如期履行對所有利害關係人的承諾。

  • Our purpose is clear, to simplify healthcare one person, one family, and one community at a time. I am confident this decision will allow both companies to better deliver on that promise and create lasting value for all stakeholders.

    我們的宗旨很清楚:一次為一個人、一個家庭與一個社區簡化醫療照護。我有信心,這項決策將使兩家公司都能更好地兌現這項承諾,並為所有利害關係人創造長期價值。

  • With that, we will now open the call for your questions. Operator?

    接下來,我們將開放提問。接線員?

  • Operator

    Operator

  • (Operator Instructions) Lisa Gill, JPMorgan.

    (接線員指示) JPMorgan 的 Lisa Gill。

  • Lisa Gill - Analyst

    Lisa Gill - Analyst

  • Good morning, thanks for taking the question. David, I cannot help but to think that on November 1, 2006, 20 years ago, CVS and Caremark came together. I know you were head of sales at Caremark at the time, so I am sure that this is a very important date for you. Can we first start with just the timing of this and the rationale? You walked through a number of the components, but if we could just maybe better understand especially the timing aspect.

    早安,謝謝讓我提問。David,我不禁想到 2006 年 11 月 1 日,也就是 20 年前,CVS 與 Caremark 合併。我知道你當時是 Caremark 的銷售主管,所以我相信這對你而言是非常重要的日期。我們能否先從這次決定的時點與其理由談起?你已經說明了多個構成要素,但如果可以的話,我們想更清楚理解,特別是時點方面的考量。

  • David Joyner - Chairman and Chief Executive Officer

    David Joyner - Chairman and Chief Executive Officer

  • Sure. Lisa, good to hear from you. Yes, I do remember 20 years ago in 2006 talking about what we were trying to build as a very different pharmacy services company, and incredibly proud of the work that we have done over the last 20 years. As I reflect back on that, I cannot help but think how much has changed since 2006 to 2026.

    當然。Lisa,很高興聽到你的聲音。是的,我記得 2006 年、也就是 20 年前,我們談到要打造一家非常不同的藥局服務公司;我也為過去 20 年我們所完成的工作感到無比自豪。回頭看那段歷程,我不禁想到從 2006 到 2026 之間改變了多少。

  • So 20 years of change, and even, quite frankly, the change that we have seen from the timing of the acquisition of Aetna. The market continues to evolve and change, and as a company, we need to continue to evolve with it. So in the two years of being in this position, I have been afforded the unique opportunity of actually thinking about this from a position of strength.

    因此,這是 20 年的變化;坦白說,甚至包括我們收購 Aetna 的時點以來所見到的變化。市場持續演進與改變,而作為一家公司,我們也必須隨之持續進化。在擔任這個職位的兩年期間,我獲得了一個獨特的機會,能夠在實力強勁的基礎上思考這件事。

  • It is eight quarters of both a beat and raise, and a financial or balance sheet that is on us ahead of schedule in terms of its leverage. So we are afforded different decisions based off of the strength of the business. I think there are two important things that I would point to. One is that most of the energy over the last two years has been focusing on the Medicare recovery, and we are now entering our third year of that important transition.

    我們已連續八個季度達成「優於預期並上調指引」,而且就槓桿水準而言,我們的財務狀況或資產負債表改善也比原計畫提前。因此,基於業務的強勁表現,我們得以做出不同的決策。我認為有兩點很重要。第一,過去兩年大部分的精力都放在 Medicare 的復甦上,而我們現在正進入這項重要轉型的第三年。

  • I think you will hear a lot of that today, but I think that actually sets the stage for the fact that we actually have what we think is a repeatable process to be able to compete effectively in that market. One thing we have not talked a lot about is the progress that we have made at retail.

    我想你今天會聽到很多相關內容,但我認為這其實為我們奠定了基礎:我們已擁有一套我們認為可重複的流程,能在該市場有效競爭。有一件我們談得不多的是,我們在零售端所取得的進展。

  • With Prem leading the recovery effort from a business that was guiding negative five two years ago to now, we are guiding our third year of growth in that business. It just creates an opportunity for us to say, what is the future of this business? How should we be organized to be able to compete effectively?

    在 Prem 帶領復甦工作下,該業務兩年前的指引仍為負 5,而現在我們已在指引中預期該業務將連續第三年成長。這讓我們有機會去思考:這項業務的未來是什麼?我們應該如何組織,才能更有效地競爭?

  • I think what we look for is the integration that matter, and what we have done the last two years is integrate quite a bit inside of CVS Health with both Caremark and Aetna and some of the healthcare delivery assets that is helping us lean into value-based care. But retail has, for the most part, for the last two decades, operated behind a firewall. So we have always had to negotiate at arm’s length. It is run independent of the business.

    我認為我們所追求的是「真正重要的整合」。過去兩年,我們在 CVS Health 內部已在 Caremark、Aetna 以及部分醫療照護交付資產之間做了相當多整合,這也幫助我們更深入推進價值導向照護。但在過去二十年中,零售端大多是在一道防火牆後運作。因此我們一直必須以獨立交易、保持距離的方式進行談判。它是獨立於其他業務運作的。

  • I think the timing of this decision is saying, now is the time, because we are not doing anything out of a distressed decision. We actually are doing it because we actually have healthy balance sheets with appropriate capital allocation opportunities and momentum in each one of the businesses that we are operating. Again, I feel really good about the timing, I feel really good about the decision, and I feel equally as important about the team that is going to allow us to execute against this plan.

    我認為這項決策的時點在於:現在就是時候了,因為我們並不是在困境下做出任何決定。我們之所以這麼做,是因為我們確實擁有健康的資產負債表、適當的資本配置機會,以及我們所經營的每一項業務都具備動能。再次強調,我對時點非常有信心,對這項決策也非常有信心,同樣重要的是,我也對能讓我們落實這項計畫的團隊充滿信心。

  • Lisa Gill - Analyst

    Lisa Gill - Analyst

  • David, if I can sneak one more in, just on the quarter and on Brian’s comments on 2027, and that is 340B. I understand it is incorporated in the way you are thinking about 2027, but really just want to understand two things. One, is this a change in the way that you are contracting? And two, Brian made the comment that you have line of sight, that it ends in 2027, it does not spill into 2028. Can you maybe just help me to understand that when I think about what is happening here and why you have line of sight that it is only going to have an impact here in 2026 and 2027?

    David,如果我可以再追問一題,關於本季以及 Brian 對 2027 年的評論,也就是 340B。我理解你們在思考 2027 年時已將其納入,但我其實想釐清兩件事。第一,這是否代表你們在簽約方式上有所改變?第二,Brian 提到你們有清楚的能見度,影響會在 2027 年結束,不會延伸到 2028 年。你能否協助我理解:當我思考這裡正在發生什麼、以及為什麼你們有能見度認為它只會在 2026 與 2027 年造成影響?

  • David Joyner - Chairman and Chief Executive Officer

    David Joyner - Chairman and Chief Executive Officer

  • Yeah, it is a great question, Lisa. I know there has been a lot of topics since our last earnings call on 340B, which is why we tried to size it as we head into 2027. Maybe I will have Brian speak a little bit about how we are thinking about HSS and then specifically 340B, and then I want to have Prem speak a little bit to how we have our arms around and how we are thinking about specifically the 340B business. Brian?

    是的,Lisa,這是個很好的問題。我知道自從我們上次財報電話會議以來,關於 340B 有很多議題,這也是為什麼我們嘗試在邁向 2027 年時把它的影響量化。也許我先請 Brian 談談我們如何看待 HSS,然後特別是 340B;接著我想請 Prem 再補充一下,我們如何掌握並思考 340B 業務本身。Brian?

  • Brian Newman - Chief Financial Officer, Executive Vice President

    Brian Newman - Chief Financial Officer, Executive Vice President

  • Sure. Thanks, David. Lisa, thanks for the question. As I think about the quarter itself, and then I will progress on to 2027, performance in HSS, Lisa, was in line with our expectations. You asked specifically about PS and 340B. Both 340B and rebate guarantee performance, we saw no surprises from our expectations.

    當然。謝謝你,David。Lisa,謝謝你的提問。就本季本身來看,接著我會延伸到 2027 年,Lisa,HSS 的表現符合我們的預期。你特別問到 PS 和 340B。無論是 340B 或回扣保證(rebate guarantee)的表現,我們都沒有看到任何超出預期的意外。

  • We also continued to see strong performance in specialty in the quarter. We maintained our guide for the full year, so not expecting any surprises balance of year. I will comment, since it is in the segment, HCD as well was consistent with our expectations, and we continue to see Oak Street perform quite well. As we thought about next year, Lisa, and looking ahead to 2027, I thought it was important to establish a floor for the HS segment, and that is effectively what we have done today.

    我們在本季也持續看到專科(specialty)業務的強勁表現。我們維持全年指引,因此預期今年剩餘期間不會有任何意外。我也補充一下,既然這屬於該分部,HCD 的表現同樣符合我們的預期,而我們也持續看到 Oak Street 的表現相當不錯。當我們思考明年、並展望 2027 年時,Lisa,我認為為 HS 分部建立一個底線很重要,而這基本上就是我們今天所做的。

  • We are confident that we would deliver at least $7 billion in HSS AOI next year. That includes the discussions around year-over-year decline in 340B next year and the impact of lower Caremark membership, those two elements. It also includes tailwinds from continued strength in specialty, as well as the second year of improvement in HCD as we make progress towards our path to profitability at Oak Street, et cetera.

    我們有信心明年至少能交付 HSS AOI 70 億美元。其中包含明年 340B 年對年下滑的討論,以及 Caremark 會員數下降的影響,這兩個因素。同時也包含來自專科業務持續強勁的順風,以及 HCD 在第二年的改善,因為我們在推進 Oak Street 的獲利路徑等。

  • Confident in our ability to manage the near-term dynamics, Lisa, and expect 2027, as I mentioned previously, to reflect trough earnings for the segment as we return to growth in 2027 as we look onward.

    Lisa,我們對於管理短期動態的能力有信心,並預期如我先前提到的,2027 年將反映該分部的獲利谷底;之後我們在 2027 年將重回成長軌道並持續向前。

  • Prem Shah - Executive Vice President, Chief Pharmacy Officer and President - Pharmacy and Consumer Wellness

    Prem Shah - Executive Vice President, Chief Pharmacy Officer and President - Pharmacy and Consumer Wellness

  • Yeah. Thanks, Brian and David. First off, thank you for the opportunity to lead CVS Pharmacy upon separation. It is an incredible opportunity, and just want to thank David and the board for that. When you think about the HSS segment, as Brian said, pharmacy services in the quarter was in line with our expectations, and we continue to feel good about our outlook for the remainder of the year.

    是的。謝謝你,Brian 和 David。首先,感謝給我在分拆後領導 CVS Pharmacy 的機會。這是一個令人振奮的機會,也想在此感謝 David 與董事會。談到 HSS 分部,如 Brian 所說,本季藥房服務(pharmacy services)的表現符合我們的預期,而我們對今年剩餘期間的展望也持續感到樂觀。

  • As we look into 2027, we are also confident in our position and our ability to manage through the transitory dynamics that we discussed prior. Coming out of the last call, I think there was two areas, 340B was one and the selling season was the second, that I want to take a few minutes to really spend a little bit more time on.

    展望 2027 年,我們同樣對自身的定位以及管理先前討論過的短暫性動態(transitory dynamics)的能力充滿信心。在上次電話會議之後,我認為有兩個領域——一個是 340B,另一個是銷售季(selling season)——我想花幾分鐘再多談一些。

  • With respect to 340B, we do not expect this to be a topic we need to discuss going forward. The level of contribution that we have in our 2027 plan is an even smaller portion of the HSS segment earnings than it has been historically. I would also reiterate that it is an important program relied on by safety net hospitals and covered entities across the country, and we do not expect the program to go away fully in the future. Secondly, when you look at the 2028 selling season, we are headed into the season with confidence.

    就 340B 而言,我們不預期未來還需要持續把它當作一個議題來討論。我們在 2027 年計畫中,340B 的貢獻占 HSS 分部獲利的比重,甚至比過去歷史水準還要更小。我也要再次強調,這是一項重要的計畫,全國各地的安全網醫院(safety net hospitals)與受涵蓋實體(covered entities)都仰賴它,而我們不預期該計畫未來會完全消失。第二,當你看 2028 年的銷售季,我們將帶著信心進入該季。

  • If you look at what the value proposition for Caremark has and has always been, it really starts with our industry-leading cost of goods, our customer focus, and our sophisticated capabilities, and our pricing model flexibility that we offer to our customers, that it really address their top concerns and priorities, which is affordability, transparency, and experience.

    如果你看 Caremark 的價值主張,過去一直如此,核心起點在於我們業界領先的商品成本(cost of goods)、以客戶為中心的聚焦、成熟的能力,以及我們提供給客戶的定價模式彈性;這些確實能回應他們最關切的議題與優先事項,也就是可負擔性、透明度與體驗。

  • Recall that 2026 for Caremark was an incredibly strong selling season. We achieved approximately $6 billion of gross new wins. As Brian said, a portion of the membership declines we expect in 2027 reflect strategic business decisions from our health plan clients, including what you saw in Aetna’s PDP book, which are not a reflection of Caremark’s offerings that we have in the marketplace.

    回想一下,Caremark 在 2026 年的銷售季表現極為強勁。我們取得約 60 億美元的新增毛贏單(gross new wins)。如 Brian 所說,我們預期 2027 年會員數下降的一部分,反映的是健康保險計畫客戶的策略性商業決策,包括你在 Aetna 的 PDP 業務中看到的情況;這並非反映 Caremark 在市場上的產品方案。

  • We expect the 2028 sales season and the new business pipeline to be robust, and we remain confident in our position and the value proposition that we’re providing into the marketplace. Finally, we have an incredibly strong and robust CVS Specialty Pharmacy business that’s focused on the patients that we serve, but more importantly, the payers that we serve.

    我們預期 2028 年的銷售季與新業務管線將會相當強勁,我們也持續對自身的市場定位與我們向市場提供的價值主張充滿信心。最後,我們擁有非常強大且穩健的 CVS 專科藥局(CVS Specialty Pharmacy)業務,聚焦於我們服務的病患,但更重要的是,我們服務的付款方(payers)。

  • Specialty continues to be a main driver of cost trend for our customers. We continue very diligent in driving competition and creating value for our payer partners, and it’s an area that we’ve invested a lot in technology and AI. We continue to make the consumer experiences seamless. We continue to really drive an integrated and a very strong offering there for the patients that we serve.

    專科業務仍然是我們客戶成本趨勢(cost trend)的主要驅動因素。我們持續非常嚴謹地推動競爭並為付款方合作夥伴創造價值;在這個領域,我們也大量投資於科技與 AI。我們持續讓消費者體驗更無縫。我們也持續為所服務的病患打造整合度高且非常強的產品與服務。

  • Overall, I would just summarize this with, we expect 2027 to represent trough earnings of at least $7 billion, and for our Health Services segment, we’re going to return to growth thereafter.

    總結來說,我們預期 2027 年將代表至少 70 億美元的獲利谷底,而對於我們的健康服務(Health Services)分部,之後將重回成長。

  • Operator

    Operator

  • Justin Lake, Wolfe Research.

    Wolfe Research 的 Justin Lake。

  • Justin Lake - Analyst

    Justin Lake - Analyst

  • Thanks. Good morning. Wanted to understand the impact of the breakup on the balance sheet and capital deployment opportunities. Specifically, I assume the rating agencies are now going to look at CVS Health as a managed care organization, meaning debt-to-cap versus debt-to-EBITDA. Wanted to hear how this might impact your leverage versus today. Then, we’ve all been expecting significant share repo into 2027 and beyond. Is there any impact on the company’s ability to deploy capital versus that $35 billion of deployable capital opportunity you discussed at the Investor Day, post the breakup? Thanks.

    謝謝。早安。我想了解分拆對資產負債表以及資本部署機會的影響。具體來說,我假設信評機構現在會把 CVS Health 視為一家管理式醫療組織(managed care organization),也就是看負債對資本(debt-to-cap),而不是負債對 EBITDA(debt-to-EBITDA)。想聽聽這可能如何影響你們相較於目前的槓桿水準。另外,我們一直預期到 2027 年及之後會有顯著的庫藏股回購。分拆之後,這是否會影響公司部署資本的能力——相較於你們在投資人日所談到的 350 億美元可部署資本機會?謝謝。

  • David Joyner - Chairman and Chief Executive Officer

    David Joyner - Chairman and Chief Executive Officer

  • Yeah. Thanks, Justin. I am going to let Brian speak to this, but I do want to just remind everybody that as we split CVS Pharmacy, the expectation is that we will have solid investment-grade positions on both of these companies. It speaks to the strength of each one of the businesses that remain in our confidence in the balance sheet and the ability to have the appropriate capital allocation flexibility. Brian, you want to

    是的。謝謝你,Justin。我會讓 Brian 回答這題,但我也想提醒大家,當我們分拆 CVS Pharmacy 時,我們的預期是這兩家公司都將維持穩健的投資等級評等。這也反映了各自業務的實力,並讓我們對資產負債表的穩健性以及具備適當的資本配置彈性感到有信心。Brian,你要不要——

  • Brian Newman - Chief Financial Officer, Executive Vice President

    Brian Newman - Chief Financial Officer, Executive Vice President

  • Yeah. Thanks, David. Justin, it is a good question, and obviously, I have spent a lot of time on the leverage, both together and some of the parts as we think about the business. I can say with a high degree of confidence that both companies will be solid investment grade with strong free cash flow generation.

    好的。謝謝你,David。Justin,這是個好問題。顯然,當我們思考這項業務時,無論是合併後或拆分成各部分,我都花了很多時間研究槓桿水準。我可以非常有信心地說,兩家公司都將維持穩健的投資等級,並具備強勁的自由現金流產生能力。

  • As you mentioned, we will target leverage or debt-to-cap metrics that are appropriate for that rating level. We will bring you along on the process, Justin, as we move throughout the next 15, 18 months. You asked about share repo as well, and I can tell you, we basically have a history of generating cash. You saw that in the guide. We raised our cash $4 billion, and my expectation to get back into the market here in the fourth quarter with the share repo program.

    如您所提到的,我們將以符合該評級水準的槓桿或債務對資本比等指標作為目標。Justin,接下來15到18個月我們推進的過程中,會讓您一路參與了解。您也問到股票回購,我可以告訴您,我們基本上一直有產生現金的歷史。您在指引中也看到了。我們把現金提高了40億美元,我預期在第四季會回到市場,啟動股票回購計畫。

  • As we think about restoring that leverage ratio and targets, we are ahead of schedule. As I look out to the future and the transaction, I would not see anything getting in the way of our ability to deploy capital going forward.

    就恢復該槓桿比率與目標而言,我們進度超前。展望未來以及這筆交易,我不認為有任何事情會妨礙我們未來部署資本的能力。

  • Operator

    Operator

  • Michael Cherny, Leerink Partners.

    Michael Cherny,Leerink Partners。

  • Michael Cherny - Equity Analyst

    Michael Cherny - Equity Analyst

  • Good morning, and thank you for taking the question. Maybe to dive a little bit on FutureCo. As you think about the business, there’s clearly been numerous instances where CVS Pharmacy and Caremark made each other better. I’m thinking of the expansion and creation of Maintenance Choice, among other different areas.

    早安,謝謝讓我提問。或許先深入談一下FutureCo。在您看待這項業務時,很明顯過去有許多例子顯示CVS Pharmacy與Caremark彼此相輔相成。我想到的是Maintenance Choice的擴張與建立,以及其他不同領域。

  • How do you think about the potential, I don’t want to call them dis-synergies specifically, but the strategic rationale for the overlap going forward between the two entities, and how the competitive differentiation that both entities have been able to generate by being together, by being aligned between the store and the PBM, that they don’t lose that capability going forward?

    您如何看待未來兩個實體之間重疊部分的潛在影響——我不想特別稱之為「去協同效應」,但就其策略理由而言——以及兩者因為在一起、因為門市與PBM之間的協同一致而能創造的競爭差異化,未來是否會失去這種能力?

  • David Joyner - Chairman and Chief Executive Officer

    David Joyner - Chairman and Chief Executive Officer

  • Yeah, it’s a great question, Michael, and something we’ve given quite a bit of thought to, because we do think that there’s something unique between CVS and Caremark, and even the role that Aetna plays in terms of engaging the pharmacist in the delivery of care.

    是的,Michael,這是個很好的問題,也是我們思考了相當多的事情,因為我們確實認為CVS與Caremark之間有其獨特之處,甚至Aetna在讓藥師參與照護交付方面也扮演著獨特角色。

  • But the unique products that we’ve built over the last 20 years are things that were going to be preserved in commercial agreements between the two organizations. We don’t need the integration in an operating structure. We need to make sure that we’re aligned around where we believe that there can be value creation and make sure that there’s an appropriate commercial agreement in place to support that.

    但我們過去20年打造的獨特產品,將會透過兩個組織之間的商業協議予以保留。我們不需要在營運架構上做整合。我們需要確保在我們相信能創造價值的方向上保持一致,並確保有適當的商業協議來支持。

  • That is, in large part, what we will be working on over the course of the next 15 to 18 months, is why the mail service is actually inside of CVS Pharmacy, because we have reinvented how pharmacy is delivered. So it’s not the traditional mail order and retail. It is basically a 90-day supply focused and organized around how the consumer wants to get their medication.

    這在很大程度上就是我們接下來15到18個月要做的工作:為什麼郵寄服務實際上是在CVS Pharmacy之內,因為我們已重新發明藥局服務的交付方式。所以這不是傳統的郵購與零售模式。它基本上是以90天用量為核心,並依照消費者希望取得藥品的方式來聚焦與組織。

  • So we can choose to deliver it to the home. They can pick it up in the store. They can come through something maybe as convenient as a drive-through. But the idea is that we’re organizing pharmacy around the consumer, and that Caremark gets the benefit of partnering with a company like CVS Pharmacy that continues to push the envelope on ways in which to better engage the consumer.

    因此我們可以選擇送到家中。他們也可以到店取貨。他們也可以透過像得來速一樣便利的方式。但核心概念是:我們以消費者為中心來組織藥局服務,而Caremark也能受益於與像CVS Pharmacy這樣持續突破、以更好方式與消費者互動的公司合作。

  • The thing that we’ve spent more time on, as opposed to the products that we built in the past, is where we’re going in the future. And that is the emphasis around the technology platform of Health100. It will be the connective tissue between the two organizations, because CVS Pharmacy becomes the engagement engine. It’s the most heavily transacted healthcare service, and as a result, more frequent transactions and a higher engagement rate with the consumer. And what Aetna and Caremark bring to the table is all the financial information to help make more informed and better decisions around their healthcare.

    相較於我們過去打造的產品,我們花更多時間在思考未來要走向哪裡。也就是圍繞Health100技術平台的重點。它將成為兩個組織之間的連結組織,因為CVS Pharmacy成為互動引擎。它是交易最頻繁的醫療保健服務,因此與消費者的交易更頻繁、互動率更高。而Aetna與Caremark帶來的是所有財務資訊,協助就醫療保健做出更有資訊基礎、也更好的決策。

  • So you connect those two, which both organizations are committed to, and we think we will build a world-class consumer engagement platform to be able to help take advantage of where we believe and see technology going, and also being able to democratize the data that we know is an important part of where healthcare is headed.

    因此把這兩者連結起來——兩個組織都承諾投入——我們認為將打造世界級的消費者互動平台,以掌握我們所相信並看到的科技發展方向,同時也能讓資料更普及化(民主化),而我們知道這是醫療保健未來走向的重要一環。

  • I think the most important takeaway is that we’ve given a lot of thought about what’s unique, that needs to be organized a certain way, which is why mail service is at CVS Retail, and it’s why we need to focus on the commercial agreement so we have the sustainability and the durability of being able to continue to organize and service the consumer.

    我認為最重要的重點是:我們已經深入思考哪些是獨特且需要以特定方式來組織的,這也是為什麼郵寄服務設在CVS零售端;同時也說明了為什麼我們必須聚焦在商業協議上,確保我們能以可持續、具韌性的方式,持續組織並服務消費者。

  • Operator

    Operator

  • Elizabeth Anderson, Evercore ISI.

    Elizabeth Anderson,Evercore ISI。

  • Elizabeth Anderson - Analyst

    Elizabeth Anderson - Analyst

  • Hi, guys. Good morning. Thanks so much for the question. Maybe one for you, Prem. I appreciate the comment you gave about the ability for the two organizations to continue to work together going forward. Prem, where do you see additional opportunities or additional areas you could focus on for the stores going forward as an independent entity that were not available to you in the current form?

    嗨,各位。早安。非常感謝讓我提問。也許有一題給您,Prem。我很感謝您提到兩個組織未來仍能持續合作的能力。Prem,若門市作為獨立實體往前走,您認為還有哪些額外機會或可聚焦的領域,是在目前架構下您無法做到的?

  • Then two, maybe David, could you just comment on where you see trend overall? You talked about obviously pockets of strength in MA, but any more details you could provide on that to just continue to understand the improving strength there? Thank you very much.

    第二題,或許David,您能否談談您對整體趨勢的看法?您提到MA(Medicare Advantage,聯邦醫療保險優勢計畫)有一些強勁的區塊,但能否提供更多細節,以便我們持續理解那裡改善中的力道?非常感謝。

  • David Joyner - Chairman and Chief Executive Officer

    David Joyner - Chairman and Chief Executive Officer

  • Yeah, perfect. Thanks, Elizabeth. I’m going to have Prem speak to where the future opportunity is, but I think it’s worth noting what we’ve done over the last two-plus years to get ourselves in a position to go build new products and services and create new opportunities. Prem, if you could just take a second talking about your priority and why we’re in a growth mode at retail and what gives you confidence that we’re going to expand into new areas.

    好的,很好。謝謝,Elizabeth。我會請Prem談談未來的機會在哪裡,但我認為也值得指出,我們在過去兩年多做了哪些事情,讓自己處於可以去打造新產品與服務、創造新機會的位置。Prem,能否花點時間談談你的優先事項,以及為什麼我們的零售端正處於成長模式、以及是什麼讓你有信心我們會擴展到新領域?

  • Prem Shah - Executive Vice President, Chief Pharmacy Officer and President - Pharmacy and Consumer Wellness

    Prem Shah - Executive Vice President, Chief Pharmacy Officer and President - Pharmacy and Consumer Wellness

  • Yeah. Thanks, David, and Elizabeth, thank you for the question. This is an incredibly exciting time, and if you look at our retail business, if you look back, and I go back three or four years when we started to talk about the changes, the intentional changes that we’re making here, historically, that was focused on really three things.

    好的。謝謝你,David,也謝謝Elizabeth的提問。這是一個令人非常振奮的時刻;如果你看我們的零售業務,回頭看三、四年前我們開始談論這些變革、也就是我們有意識地在這裡推動的變革,歷史上主要聚焦在三件事。

  • First and foremost, we invested in the technology platform to create better experiences. If you think about just some clear examples, AI now supports our pharmacy workflow for 85% of our prescriptions. Second, we invested in our colleagues.

    第一也是最重要的,我們投資於技術平台以創造更好的體驗。舉一些明確例子,AI現在支援我們藥局工作流程中85%的處方。第二,我們投資於同仁。

  • We know that our 30,000 pharmacists, we know that our 200,000 store colleagues are essential components to deliver healthcare locally, and we know that healthcare is done by humans in our local communities, and we have a tremendous focus on ensuring that our colleagues are enabled and successful in everything that they do.

    我們知道我們的3萬名藥師、我們的20萬名門市同仁,是在地提供醫療保健不可或缺的關鍵要素;我們也知道醫療保健是在我們的在地社區由人來完成的,因此我們非常專注於確保同仁在所做的一切事情上都能被賦能並取得成功。

  • Lastly, I think some of the things that we focused on around customer NPS, so the customers that walk in our stores, how do we really improve that experience for them? How do we make that omnichannel? How do we make it consistent across the board? These are three areas we really spent a lot of time focusing on, and you can see that flow through in our results in this quarter, right? As you saw in the quarter, our comp scripts grew 3.9%, but also, we were also able to take advantage of new opportunities.

    最後,我想是我們在客戶NPS方面所聚焦的一些事情:走進我們門市的顧客,我們如何真正改善他們的體驗?如何做到全通路(omnichannel)?如何做到各方面一致?這三個領域我們投入了大量時間聚焦,而你也可以在本季的結果中看到反映,對吧?如你在本季看到的,我們的同店處方量成長3.9%,同時我們也能把握新的機會。

  • I think GLP-1s is another great example. Our scripts in GLP-1s this quarter grew 23%, and it’s because we took action. We made access more affordable. We made it easier for patients to show up. I mean, we really drove focus on what’s most important for the people walking into our stores.

    我認為 GLP-1 類藥物是另一個很好的例子。我們本季在 GLP-1 類藥物的處方量成長了 23%,這是因為我們採取了行動。我們讓取得用藥的成本更可負擔。我們讓病患更容易到店就診/取藥。我的意思是,我們確實把重點放在對走進我們門市的人最重要的事情上。

  • Lastly, I think it’s really important to talk about our evolution of the reimbursement model. We focused on that over time with CVS CostVantage, and let me just be really clear. The CVS and Caremark relationships have operated behind a firewall for more than two decades, so this is something that we continually do, but we continue to be focused on the value proposition that we create to payers.

    最後,我認為談到我們報銷模式的演進非常重要。我們隨著時間推進,透過 CVS CostVantage 持續聚焦於此,我想把話說得很清楚。CVS 與 Caremark 的關係在超過二十年的時間裡一直是在防火牆後運作,因此這是我們持續在做的事情,但我們也持續聚焦於我們為付款方所創造的價值主張。

  • As I look forward, I think the excitement I have in our CVS Pharmacy asset is we have a well-run, strong service offering for the customers we serve. We’re in a position now to offer incremental healthcare services, leverage our 9,000 stores, leverage our footprint in very different ways, because the key thing for almost all payers, I don’t care who you are in this country, is we have a challenge with affordability.

    展望未來,我對我們 CVS Pharmacy 資產感到興奮之處在於:我們為所服務的客戶提供了一個營運良好、服務能力強的方案。我們現在有條件提供更多的醫療健康服務,運用我們 9,000 家門市,並以非常不同的方式運用我們的據點版圖,因為對幾乎所有付款方而言——不管你在這個國家是誰——關鍵在於我們面臨可負擔性的挑戰。

  • CVS Pharmacy affords and has the privilege to serve in every community, standardize healthcare services, and transform the industry in terms of what we can do, and this will afford us the right to really drive this forward into the marketplace.

    CVS Pharmacy 有能力、也有榮幸在每個社區提供服務,將醫療健康服務標準化,並在我們能做的事情上推動產業轉型,而這也將賦予我們在市場上真正把這件事往前推進的正當性。

  • David Joyner - Chairman and Chief Executive Officer

    David Joyner - Chairman and Chief Executive Officer

  • That’s perfect. Prem is effectively running America’s pharmacy, and we say this all the time. We think this country needs CVS Pharmacy and the community-based services that we’re providing because we are investing in the communities, and we’re going to continue to extend that reach as we go forward.

    這非常到位。Prem 實際上是在經營美國的藥局體系,我們一直都這麼說。我們認為這個國家需要 CVS Pharmacy 以及我們所提供的以社區為基礎的服務,因為我們正在投資社區,而且未來也會持續擴大觸及範圍。

  • Now, if I could just speak to the remaining CVS Health organization and to Prem’s point about this focus on affordability, we think the focus will now be purely on what we believe are the drivers of healthcare in this country. If you look at two-thirds of the spend coming from both the health systems and the drug manufacturers, with increases that, in most cases, are high single or low double digits, there is a significant opportunity for this organization to tackle that challenge on behalf of the customers in which we serve.

    現在,如果我可以談談 CVS Health 組織其餘部分,以及呼應 Prem 對可負擔性聚焦的觀點,我們認為接下來的重點將會純粹放在我們相信是推動本國醫療健康的驅動因素上。如果你看支出結構,有三分之二的支出來自醫療體系與藥品製造商,而其增幅在多數情況下是高個位數到低雙位數,這個組織就有很大的機會代表我們所服務的客戶去應對這項挑戰。

  • We are declaring that the company that will remain will be focused to support the payers and bring affordability and improving access. Steve, you want to just give a little bit of color on the trend environment and how we’re looking, maybe just on Medicare as an example?

    我們宣示,未來保留下來的公司將聚焦於支持付款方,提升可負擔性並改善取得(access)。Steve,你要不要就趨勢環境以及我們的觀察補充一些說明,也許以 Medicare 作為例子?

  • Unidentified Company Representative

    Unidentified Company Representative

  • Sure. Thanks, David. Good morning, Elizabeth. Aetna’s had a strong quarter, as we talked about. Really nice progress across all the businesses at Aetna as we return the business to target margins. I’ll just specifically comment on Medicare. We have seen some pockets of favorability. It continues to be a high-trend environment generally, but as we’ve laid down the foundation for this business over the last couple years, we’ve seen tremendous improvement, and we’re going to build on that.

    當然。謝謝你,David。早安,Elizabeth。如同我們談到的,Aetna 本季表現強勁。隨著我們把業務帶回目標利潤率水準,Aetna 各項業務都有非常好的進展。我特別談一下 Medicare。我們看到某些面向出現有利的表現。整體而言仍然是高趨勢(high-trend)的環境,但在過去幾年我們為這項業務打下基礎之後,我們看到顯著改善,而且我們會在此基礎上持續推進。

  • We took the same discipline into our 2027 pricing, assumed trends remained elevated, and the priorities were unchanged. We were going after one more year of margin improvement, and we pulled several levers to achieve that. We obviously, as you could see, we did make some adjustments to benefits, but beyond that, we made adjustments to our geography, our product mix.

    我們以同樣的紀律來制定 2027 年的定價,假設趨勢仍維持在高檔,而優先事項並未改變。我們要再爭取一年利潤率改善,並透過多項槓桿來達成。很明顯地,如你所見,我們確實對給付內容做了一些調整,但除此之外,我們也調整了地理布局與產品組合。

  • We brought leading star scores into 2027 payment year. We made adjustments to our networks. We had the highest performing providers in the markets where we wanted to perform. We’ve built robust capabilities around medical cost management. All those levers we were able to put into place as we think about 2027.

    我們把領先的星級評分(Star Scores)納入 2027 支付年度。我們也調整了我們的網絡。在我們希望表現突出的市場中,我們配置了表現最佳的醫療提供者。我們建立了強健的醫療成本管理能力。當我們思考 2027 年時,這些槓桿我們都能夠到位。

  • Just a little insight here, early into AEP, but so far, it’s playing out exactly as we expected. We’ll be able to give more color to that as we complete AEP. This business is performing really well, and we expect another year of margin improvement with some modest growth, actually. The benefits ability we’re able to put into the marketplace is, I think, going to be important as we think about high retention of our current members. That helps engage the members, creates actually better healthcare costs, and a higher satisfaction.

    再補充一點洞見:AEP 才剛開始不久,但到目前為止,進展完全符合我們的預期。等我們完成 AEP 後,我們會提供更多細節。這項業務表現非常好,我們預期利潤率還會再改善一年,同時其實也會有一些溫和成長。我們能夠投放到市場上的給付方案能力,我認為對於維持現有會員的高留存率會很重要。這有助於提升會員參與度,實際上也能帶來更好的醫療成本表現與更高的滿意度。

  • So, really like the position of the business. We have more work to do, still a high trend environment, but we are lining up a lot of capabilities at Aetna with our investment in technology and the tools we are putting into place. We really think we have an opportunity to impact the affordability and access issue that is so much needed in our healthcare system.

    因此,我們非常喜歡目前這項業務所處的位置。我們還有更多工作要做,環境仍然是高趨勢,但我們正透過對科技的投資以及我們正在部署的工具,在 Aetna 建構並對齊許多能力。我們確實認為,我們有機會對醫療體系中極度需要解決的可負擔性與取得(access)問題產生影響。

  • Operator

    Operator

  • Erin Wright, Morgan Stanley.

    Erin Wright,Morgan Stanley。

  • Erin Wright - Analyst

    Erin Wright - Analyst

  • Hi. Good morning. Can you speak to the rationale for retaining Specialty at CVS Health and how you see the long-term drivers and synergies playing out as also alongside the PBM becomes more stable, more of a fee-for-service business over time? Do you see opportunities to further lean into Specialty as that becomes a larger component of RemainCo or CVS Health?

    嗨,早安。你能談談在 CVS Health 保留 Specialty(專科藥/專科藥房)業務的理由嗎?以及當 PBM 隨時間推進變得更穩定、更多轉向按服務收費(fee-for-service)的業務時,你如何看待長期驅動因素與協同效應的發展?你是否看到進一步加碼 Specialty 的機會,讓它成為 RemainCo 或 CVS Health 更大的組成部分?

  • David Joyner - Chairman and Chief Executive Officer

    David Joyner - Chairman and Chief Executive Officer

  • Yeah, it is a great question, Erin, and I think you are hearing two things from the remaining CVS Health organization, and that is the focus on affordability and access. It also is the role that we play in trying to tackle those challenges for our customers.

    是的,這是個很好的問題,Erin。我認為你從保留下來的 CVS Health 組織聽到兩件事:聚焦可負擔性與取得(access)。以及我們在協助客戶應對這些挑戰時所扮演的角色。

  • Steve just talked a lot about Medicare. It is a growing part of the business as we have an aging population, and we believe that there is an important step from moving from a fee-for-service operating environment to value-based care. That piece is a heavy investment for the business, and we need to make sure we have the appropriate assets that create the synergistic and the value prop for how we are going to tackle those unique high-acuity populations. The same thing holds true on specialty, and we have talked for a long time. I started in 1993 with Caremark.

    Steve 剛才談了很多 Medicare。隨著人口老化,這是業務中成長的一部分,而我們相信,從按服務收費(fee-for-service)的營運環境轉向價值導向照護(value-based care)是重要的一步。這一塊需要大量投資,我們必須確保擁有適當的資產,才能形成協同效應與價值主張,來應對那些獨特的高病況嚴重度(high-acuity)族群。在 Specialty 方面也是同樣道理,我們談了很久。我在 1993 年加入 Caremark。

  • It was leading the part of how specialty integrates into the PBM. If I fast-forward 30-plus years later, there is 2% of this population that is driving more than 50% of the spend of pharmacy, and it is growing at a rate that is not affordable, and it is not sustainable. It is why you need all of the levers of a classic PBM in order to continue to attack the rising drug cost and the way in which we create competition. We think the synergistic opportunity with the PBM and specialty remains intact because that is, again, one of the most important priorities for the customers that we are serving. That is part of the logic of keeping it together.

    當時就在引領 Specialty 如何整合進 PBM。若我把時間快轉到 30 多年後,只有 2% 的人口卻驅動了超過 50% 的藥品支出,而且其成長速度已經不可負擔、也不可持續。這就是為什麼你需要經典 PBM 的所有槓桿,才能持續對抗藥價上升,以及我們如何創造競爭。我們認為 PBM 與 Specialty 的協同機會仍然完整存在,因為這同樣是我們所服務客戶最重要的優先事項之一。這也是把它們維持在一起的邏輯之一。

  • As I look specifically at the integration that matters, which I mentioned on the front end of the call, this has been a really interesting eight years in terms of bringing the businesses together. What Aetna has been able to gain through the combination of the assets is a world-class PBM. Aetna is far more sophisticated and far more effective in managing their pharmacy benefit in addition to total cost of care because of the assets that Caremark and our specialty business brings to the table.

    就我具體來看真正重要的整合——我在電話會議一開始提到過——過去八年把各項業務整合在一起的過程非常有意思。Aetna 透過資產組合所獲得的是世界級的 PBM。由於 Caremark 與我們 Specialty 業務所帶來的資產,Aetna 在管理藥房福利以及整體照護成本方面,變得更成熟、也更有效率。

  • On the flip side of this, Caremark has been far more effective in terms of thinking about the role of pharmacy and how it impacts the total cost of care, because it is outside of just the pharmacy benefit, and it is the role that actually medications play in managing the total cost of care, of which Aetna is managing the total risk. There has been a really interesting and, I think, evolving integration opportunities between the businesses, and I expect that that will continue as we find new markets and new opportunities.

    另一方面,Caremark 在思考藥局的角色以及其如何影響整體醫療照護總成本方面,成效要好得多,因為這不僅僅侷限於藥品福利本身,而是著眼於藥物在管理整體照護總成本中實際扮演的角色;而 Aetna 正在管理其中的整體風險。兩項業務之間存在非常有意思、而且我認為仍在演進中的整合機會;隨著我們發掘新市場與新機會,我預期這種整合將會持續。

  • This is, in large part, delivered to both our Medicare population and equally as important to the commercial platforms and franchises that we have across both Aetna and Caremark. Medicaid becomes very complementary to the business because these are high-risk populations and actually in markets that complement the roles that we’re playing with Medicare and even the providers that we’re working with across commercial.

    這在很大程度上同時提供給我們的 Medicare 族群;同樣重要的是,也提供給我們在 Aetna 與 Caremark 兩端所擁有的商業平台與特許經營業務。Medicaid 對這項業務形成很強的互補,因為這些是高風險族群,而且實際上位於能夠補強我們在 Medicare 所扮演角色的市場,甚至也能補強我們在商業保險領域與各家醫療服務提供者合作的布局。

  • Next question, operator.

    下一個問題,接線員。

  • Operator

    Operator

  • Stephen Baxter, Wells Fargo.

    Wells Fargo 的 Stephen Baxter。

  • Stephen Baxter - Analyst

    Stephen Baxter - Analyst

  • Yeah. Hi. Thanks. You’ve touched on the, I guess, the capital and strategic parts of this, but if we think purely about the operating cost structure, we can look back to the original Caremark and CVS transactions or the more recent CVS-Aetna transactions and just see that operating cost synergies were a big part of the financial rationale of those deals. I know it’s early, but I guess how are you thinking about what the potential financial dis-synergies could be, and any color on whether you think they’ll sit entirely in the newly created CVS Pharmacy business, or I guess shared or allocated across the two businesses? Thank you.

    是的,嗨,謝謝。你們已經談到這件事在資本與策略面的部分;但如果我們純粹從營運成本結構來看,回顧最初的 Caremark 與 CVS 交易,或是較近期的 CVS-Aetna 交易,都可以看到營運成本綜效是那些交易財務理由中的重要一環。我知道現在還早,但我想問你們如何看待潛在的財務「反綜效」(dis-synergies),以及能否補充一下你們認為這些反綜效會完全落在新成立的 CVS Pharmacy 業務之內,還是會在兩項業務之間共享或分攤?謝謝。

  • David Joyner - Chairman and Chief Executive Officer

    David Joyner - Chairman and Chief Executive Officer

  • Yeah, so let me start, and I’ll let Brian finish. We obviously are contemplating some one-time costs, and so that has been contemplated in our guidance and how we’re thinking about the future, but we feel like these are all manageable. As we look at the opportunities that we’ve been describing on today’s call, we think this will more than offset some of those expenses. Brian, I don’t know if you have anything else to add.

    好的,我先開始,然後讓 Brian 補充。我們顯然正在考量一些一次性成本,因此這已反映在我們的財測指引以及我們對未來的思考中;但我們認為這些都是可控的。就我們今天電話會議所描述的機會而言,我們認為這些機會將足以抵銷其中一部分費用。Brian,我不確定你是否還有要補充的。

  • Brian Newman - Chief Financial Officer, Executive Vice President

    Brian Newman - Chief Financial Officer, Executive Vice President

  • Yeah, thanks, David. Steven, I’d just offer that, when we looked at the deal, the strategic value created by taking this action is going to far outweigh any dis-synergies. As I look at the run rate AOI impact of any stranded or public company cost, as well as any one-time cost, they’re certainly manageable, and in line with other transactions of this type.

    好的,謝謝你,David。Steven,我想補充的是,當我們評估這筆交易時,採取這項行動所創造的策略價值,將遠遠大於任何反綜效。就任何被遺留成本或上市公司成本(public company cost)的常態化 AOI(調整後營業利益)影響,以及任何一次性成本而言,這些當然都是可控的,也與同類型交易的情況一致。

  • We’re going to look to offset any run rate costs over time, including pursuing opportunities created by a simpler independent structure that David referenced earlier. As you said, it’s early in the process, so expect us to come back with more details as we progress through the separation, but I’m confident that we certainly can manage any dis-synergies there.

    隨著時間推進,我們會尋求抵銷任何常態化成本,包括追求 David 先前提到、由更簡化且獨立的架構所帶來的機會。如你所說,目前仍在早期階段,因此在分拆推進的過程中,請期待我們回來提供更多細節;但我有信心,我們確實能夠管理任何相關的反綜效。

  • Operator

    Operator

  • Andrew Mok, Barclays.

    Barclays 的 Andrew Mok。

  • Andrew Mok - Analyst

    Andrew Mok - Analyst

  • Hi, good morning. I just wanted to make sure I understand your 2027 EPS outlook of $8.65 in the context of all of today’s results and announcements. Given the $0.20 raise to this year’s EPS guidance, it does not look like you are assuming much EPS contribution from the resumption of share repurchase in 2027. Can you help us understand that dynamic and whether there are any other offsets embedded in the outlook, including breakup costs you might incur next year? Thanks.

    嗨,早安。我想確認我是否正確理解你們在結合今天所有業績與公告後,對 2027 年 EPS 為 8.65 美元的展望。鑑於你們把今年 EPS 指引上調了 0.20 美元,看起來你們並沒有假設 2027 年恢復庫藏股回購會帶來太多 EPS 貢獻。你們能否協助我們理解這個動態,以及展望中是否還包含其他抵銷因素,包括你們明年可能產生的分拆成本?謝謝。

  • David Joyner - Chairman and Chief Executive Officer

    David Joyner - Chairman and Chief Executive Officer

  • Go ahead, Brian.

    Brian,你來回答。

  • Brian Newman - Chief Financial Officer, Executive Vice President

    Brian Newman - Chief Financial Officer, Executive Vice President

  • Yeah, so you are reading it right, which is we took the guide this year up $0.20, and effectively flowed that through. We had talked about an $8.44 floor next year, so now it is $8.65, rounded up a penny. So, we are at $8.65 next year. That only assumes the offset of dilution in share repo. As you can imagine, as cash is back, leverage is where we want it to be, we have got some dry powder to leverage. Net-net, what is implied in the guide next year where we set a floor, is just the offset of dilution. Hopefully that answers your question.

    好的,你的解讀是正確的:我們把今年的指引上調 0.20 美元,基本上也把這個增幅延續反映進去。我們先前談到明年的底線(floor)是 8.44 美元,所以現在是 8.65 美元,四捨五入多了 0.01 美元。因此,我們明年是 8.65 美元。這只是假設以回購來抵銷股份回購相關的稀釋影響。如你所想像,當現金回來、槓桿回到我們希望的水準時,我們會有一些可運用的「火藥」(dry powder)。總結來說,明年指引中我們設定底線所隱含的,就是僅抵銷稀釋。希望這回答了你的問題。

  • Operator

    Operator

  • Ann Hynes, Mizuho.

    Mizuho 的 Ann Hynes。

  • Ann Hynes - Analyst

    Ann Hynes - Analyst

  • Great, thank you. I know that you said 2028 should be on the higher end of your range you provided at Investor Day. Are you ready to give any kind of growth algorithms, whether on operating income or EPS, for the two new companies on a standalone basis? Thanks.

    很好,謝謝。我知道你們說 2028 年應該會落在投資人日所提供區間的較高端。你們是否準備好提供任何成長公式(growth algorithms),無論是針對營業利益或 EPS,來描述兩家新公司在獨立運作(standalone)基礎下的表現?

  • David Joyner - Chairman and Chief Executive Officer

    David Joyner - Chairman and Chief Executive Officer

  • Yeah, go ahead, Brian. We are not really guiding beyond 2028 at this point, and Brian, you

    好的,Brian 你先。我們目前其實不太提供 2028 年以後的指引,Brian,你……

  • Brian Newman - Chief Financial Officer, Executive Vice President

    Brian Newman - Chief Financial Officer, Executive Vice President

  • Yeah, I was thinking back to Investor Day, and we set out a roadmap, which was in the mid-teens, which gets us to the 2028 horizon. We are tracking well against that. We always talked about multiple paths to get there. I think the businesses are performing very well. We just took 2026 up again. That is a dollar over where we started.

    是的,我回想投資人日,我們提出了一個路線圖,也就是中十幾(mid-teens)的水準,帶我們走到 2028 年的時間點。我們目前的進度追蹤良好。我們一直說有多條路徑可以達成。我認為各項業務表現都非常好。我們剛剛又把 2026 年上調。那比我們一開始的基準高出 1 美元。

  • We just put a floor in for 2027, and by signaling that we are going to be at the upper end, in the upper end of mid-teens by 2028, I just wanted to give the street confidence that we are on track to meet or exceed our expectations. But we will come back to you on the February call, and we will talk more about the details around the 2027 guide, and that will give you a firmer base.

    我們也為 2027 年設定了底線;而透過釋出訊號表示到 2028 年我們將落在中十幾(mid-teens)區間的上緣、也就是較高端,我只是想讓市場對我們正按計畫達成或超越預期更有信心。不過我們會在 2 月的電話會議再回來,進一步談 2027 年指引的細節,讓你們有更穩固的基礎。

  • David Joyner - Chairman and Chief Executive Officer

    David Joyner - Chairman and Chief Executive Officer

  • Yeah, so I mean, this is all a timing issue. We gave headwinds and tailwinds early last quarter than we normally do, and we will be back in February with more clarity. And maybe just a reminder in case people are questioning this, we are doing this out of a position of strength. We do not have to make the decisions, and as we are looking at the business and how it is performing, we have confidence, and we are actually doing this because we believe this is the right thing to do for the long-term growth of the business, not because there is any issue that may be on the horizon in 2028.

    是的,我的意思是,這完全是時點問題。我們在上一季比平常更早提供了逆風與順風因素,我們會在 2 月帶來更清楚的說明。另外也提醒一下,以免有人質疑:我們是在強勢地位下做這件事。我們不必被迫做出決策;而在我們檢視業務及其表現時,我們有信心。我們之所以這麼做,是因為我們相信這對業務的長期成長是正確的事,而不是因為 2028 年地平線上可能會出現任何問題。

  • Operator

    Operator

  • Scott Fidel, Goldman Sachs.

    Goldman Sachs 的 Scott Fidel。

  • Scott Fidel - Analyst

    Scott Fidel - Analyst

  • Hi, thanks. Good morning. Wanted to just go back to the margin improvement and expansion that’s been sustaining over at Aetna, and where you are specifically in that journey. Clearly, Medicare Advantage being the particular driver of that.

    嗨,謝謝。早安。我想回到 Aetna 那邊持續的利潤率改善與擴張,以及你們在這段旅程中目前具體處於哪個階段。顯然,Medicare Advantage 是其中的特定驅動因素。

  • It seems like at this point, based on your updated guidance, you’ve probably breached into getting towards, I would think, a very low level of profitability back in the Medicare Advantage business for 2026 inside of the guidance. Just wanted to confirm that, and then, I know, Steve, you mentioned how, I think you said, another one more year of focused margin improvement targeted for 2027.

    看起來在這個時間點,根據你們更新後的指引,你們可能已經在指引中,讓 2026 年的 Medicare Advantage 業務回到非常低度的獲利水準。我想確認是否如此;另外我知道 Steve,你提到我想你是說,2027 年還會再有一年聚焦的利潤率改善。

  • Should I read into that anything in terms of where you expect to take the margins for 2027 back towards target, or is this still a multi-year journey in terms of getting back to that 3%-4% target margin for Medicare Advantage? Thanks.

    我是否應該從中解讀出任何訊息,關於你們預期在 2027 年把利潤率拉回目標的路徑?還是說,這仍然是一段需要多年時間、才能回到 Medicare Advantage 3%–4% 目標利潤率的旅程?謝謝。

  • David Joyner - Chairman and Chief Executive Officer

    David Joyner - Chairman and Chief Executive Officer

  • Go ahead, Steve.

    請繼續,Steve。

  • Unidentified Company Representative

    Unidentified Company Representative

  • Sure. Thanks. I can confirm the business is still on its multi-year journey, but it is ahead of expectations. We are moving into the profitable territory in 2026, so I can confirm that. As we look to 2027, we are going to expand on that for the reasons I indicated earlier. Just maybe a couple more thoughts as we think about the business and why we are so confident in the margin expansion 2027.

    好的,謝謝。我可以確認,這項業務仍在其多年期的轉型旅程中,但進度已超出預期。我們將在 2026 年進入獲利區間,這點我可以確認。展望 2027 年,基於我先前提到的原因,我們會在此基礎上進一步擴大。再補充幾點,談談我們如何看待這項業務,以及為什麼我們對 2027 年的利潤率擴張如此有信心。

  • Beyond the levers that I talked about, the repositioning of the holistic Medicare. As we think about our Part D standalone was performing well, we did a reset there. That is going to contribute our group Medicare Advantage business. We talked about that as we got through 2027, we would have about 75% of the book repriced. That is very much on track.

    除了我提到的那些槓桿之外,還包括整體 Medicare(holistic Medicare)的重新定位。就我們的 Part D 單獨計畫而言,表現一直不錯,我們也在那裡做了重置。這將會對我們的團體 Medicare Advantage 業務帶來貢獻。我們也提到,到了 2027 年,我們大約會有 75% 的業務組合完成重新定價。這項進度非常符合預期。

  • Holistically, as you think about it, as I said, we were able to add stability, so we will be able to see some modest growth in the areas that we want to see that growth. All this kind of comes together just as we hoped and we planned for, and strong execution by the team, and so really proud of where we are. It is positioned nicely to go into 2027 with another year of nice margin expansion.

    從整體來看,正如我所說,我們已經能夠提升穩定性,因此在我們希望看到成長的領域,將能看到一些溫和的成長。這一切都如同我們所希望、所規劃的那樣逐步到位,加上團隊強而有力的執行,所以我對我們目前的進展感到非常自豪。這也讓我們在邁向 2027 年時具備很好的態勢,並可望再迎來一年可觀的利潤率擴張。

  • David Joyner - Chairman and Chief Executive Officer

    David Joyner - Chairman and Chief Executive Officer

  • Great. Thanks, Steve. All right, operator, I think we have time for one more question.

    很好。謝謝你,Steve。好的,接線員,我想我們還有時間再接一個問題。

  • Operator

    Operator

  • George Hill, DB.

    George Hill,DB。

  • George Hill - Analyst

    George Hill - Analyst

  • Yeah. Thanks, guys, and I appreciate you taking the question. I guess, David, just to kind of round this out, I would ask, as we think about the future split up, what changed? I guess, could you talk a little bit more about what changed in the outlook in healthcare from a year ago versus where you are now? Could you talk about how you saw each business, what was competitively disadvantaged and what becomes competitively advantaged through the split up? I will end it there. Thanks.

    是的,謝謝各位,也感謝你們讓我提問。我想,David,為了把這件事完整收尾,我想問的是:當我們思考未來拆分後的樣貌時,究竟是什麼改變了?你能否多談一些,相較於一年前,現在你們對醫療保健業務的展望有哪些變化?也請談談你們如何看待各項業務:哪些在競爭上處於劣勢,而透過拆分後又有哪些會轉為競爭優勢?我就問到這裡。謝謝。

  • David Joyner - Chairman and Chief Executive Officer

    David Joyner - Chairman and Chief Executive Officer

  • Yeah. George, thanks for the question. Maybe I will end the way I started. Two years ago when I took this job, we did not have the ability to make decisions like this because we were struggling on our Medicare business. PCW was guiding down 5%, and we were focused purely on running and operating this business against what we knew we were capable of doing.

    好的,George,謝謝你的問題。也許我會用我一開始的方式來作結。兩年前我接下這份工作時,我們沒有能力做出這樣的決策,因為我們的 Medicare 業務正處於困境。PCW 當時指引下修 5%,我們完全專注在把這項業務跑好、營運好,並對照我們知道自己有能力做到的水準去執行。

  • I look two years later, and the say-do ratio that Brian has been so consistent on in terms of making sure that we under-promise and over-deliver, and we have been eight quarters of delivering on that. What has changed in two years is the fact that we now can look at this business and the assets that are assembled and really determine, without any distress or without anything that we have to do, on what is the right strategic decision to make.

    兩年後回頭看,Brian 一直非常一致地強調「說到做到」的比例,確保我們低承諾、高交付,而我們已經連續八個季度做到交付。兩年來最大的改變在於:我們現在可以在沒有壓力、也不需要被迫做任何事的情況下,審視這項業務以及已組合起來的資產,並真正判斷什麼才是正確的策略決策。

  • As we said, CVS Pharmacy has been operating behind a firewall for the last two decades. It has always been an arm’s length negotiation and structure, which again, just reinforces the fact that there are integration opportunities, but nothing that we cannot solve for with a commercial agreement.

    如同我們所說,CVS Pharmacy 在過去二十年一直是在防火牆後運作。一直以來都是保持一定距離的談判與架構安排;這再次強化了一點:確實存在整合機會,但沒有任何事情是我們無法透過商業協議來解決的。

  • What is powerful and where we see healthcare going is in the area of technology. How do we make sure that we capitalize on this next wave of change that we know is going to be very prevalent inside the healthcare space and make sure we leverage everything that we actually have in this current enterprise and preserve it for the future? That is why we are spending as much time on connecting and integrating where we believe it matters. We are preserving the CVS and Aetna integration.

    真正強而有力、也是我們看到醫療保健未來走向的,是科技領域。我們要如何確保能把握下一波變革?我們知道這股變革將在醫療保健領域非常普遍;同時也要確保我們能運用目前企業體內實際擁有的一切,並為未來保留下來。這就是為什麼我們花這麼多時間在我們認為重要之處進行連結與整合。我們正在保留 CVS 與 Aetna 的整合。

  • We are preserving the Oak Street and Aetna and Signify, and we are also now focusing on areas that we know we can capitalize on the future around technology. I would just say, I could not be happier and more proud of the team’s performance that led us to a place where we could make the decisions out of strength, and also the fact that we believe this is the right thing for all stakeholders involved.

    我們也在保留 Oak Street 與 Aetna 以及 Signify 的整合;同時,我們現在也把重點放在我們知道能在未來、圍繞科技而加以把握的領域。我只能說,我對團隊的表現感到無比開心與自豪;正是這樣的表現讓我們能在強勢的狀態下做出決策;同時我們也相信,這對所有相關利害關係人而言都是正確的事。

  • We believe we are going to serve our consumers more effectively, we are going to serve our customers more effectively, and hopefully that will actually be viewed favorably from the shareholders that are investing in this company. In closing, I just want to thank everyone for joining this morning. We are incredibly excited about this next step in our evolution.

    我們相信,我們將能更有效地服務消費者、更有效地服務客戶,而希望這也能讓投資本公司的股東以更正面的角度看待。最後,我想感謝今天早上加入的各位。我們對於演進過程中的下一步感到無比振奮。

  • I want to specifically thank our colleagues across the country and across this company that work and the work that they do every day to serve our customers. Their dedication and relentless commitment to those we serve has built the foundation for everything we’ve discussed today. We’ve taken this deliberate action to create long-term value and do even more to deliver on our purpose, to simplify healthcare one person, one family, and one community at a time. I look forward to keeping you updated on our progress.

    我也想特別感謝遍布全國、以及公司各處的同仁,感謝他們每天為服務客戶所付出的努力。他們的投入與對服務對象不懈的承諾,奠定了我們今天所討論一切的基礎。我們採取這項審慎的行動,是為了創造長期價值,並更進一步實現我們的使命:一次一個人、一次一個家庭、一次一個社區,簡化醫療保健。我期待持續向各位更新我們的進展。

  • Operator

    Operator

  • Thank you for joining CVS Health’s third-quarter 2026 earnings call. This concludes today’s conference call. You may now disconnect.

    感謝您參加 CVS Health 2026 年第三季財報電話會議。今天的電話會議到此結束。您現在可以掛線。